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Purpose: Cardiovascular diseases (CVDs) are extremely common among the elderly, but 
information on the use of potentially inappropriate medications (PIMs) with cardiovascular 
risk is scarce. We aimed to determine the prevalence of PIMs with risk of cardiac and cere-
brovascular adverse events (CCVAEs), including major adverse cardiac and cerebrovascular 
events (MACCE).
Patients and methods: A cross-sectional study was performed using a convenience sample 
from four long-term care facilities and one community pharmacy in Portugal. Patients were 
included if they were aged 65 or older and presented at least one type of medication in their 
medical and pharmacotherapeutic records from 2015 until December 2017. The main outcome 
was defined as the presence of PIMs with risk of MACCE and was assessed by applying a 
PIM-MACCE list that was developed from a previous study. All medications included in this 
list were assessed for their availability in Portugal.
Results: A total of 680 patients were included. Of those, 428 (63%) were female with a mean 
age of 78.4±8.1 years. Four-hundred and four (59.4%) patients were taking medications asso-
ciated with CCVAEs risk (mean =1.7±1.0 drugs/patient), including 264 patients (38.8%) who 
used drugs with MACCE risk (mean =1.4±0.8 drugs/patient). Fifty percent of patients with a 
previous history of CVD (n=521) were taking PIMs with risk of CCVAEs, including 30.0% 
with risk of MACCE.
Conclusion: Our findings show that 50% of patients with previous history of CVD were taking 
drugs with risk of CCAVEs and 30% with risk of MACCE. More tailored tools for the manage-
ment of drug therapy in elderly patients with CVD are of major importance in clinical practice.
Keywords: patient safety, therapeutic uses, outcome process assessment (health care), cardio-
vascular risk, NSAIDs, antipsychotics
Introduction
The elderly are usually fragile and more susceptible to drug-related problems as a 
result of multimorbidity, polypharmacy, and physiological changes that affect the 
pharmacokinetics and pharmacodynamics of drugs.1 Therefore, this population is more 
prone to using medications that can be considered inappropriate.
A potentially inappropriate medication (PIM) is any medication used by a patient 
that could introduce a significant risk of an adverse drug reaction (ADR), in particular 
when there is an equally or more effective alternative with lower risk available. 
In the elderly, ADRs can sometimes be difficult to recognize as they often present 
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with unspecific symptoms (eg, falls, fatigue, and orthostatic 
hypotension). ADRs are observed 2–3 times more often in the 
elderly and account for 5%–17% of all hospital admissions.2 
A systematic review has found a mean prevalence of ADRs 
in the elderly of 11% (95% CI: 5.1%–16.8%) and a preva-
lence of ADRs leading to hospitalization of 10% (95% CI: 
7.2–12.8). These authors have also shown that increased 
comorbid complexity and increased number of medications 
were significantly associated with an increased risk of ADRs.3 
It is estimated that 30%–60% could be prevented.2 A recent 
study has shown that 45.1% (95% CI: 33.1%–57.2%) of the 
ADRs leading to hospitalization were preventable.4 In the 
USA and Canada, the prevalence ranged between 14% and 
37.0%;5 in Europe, the prevalence ranged between 23% and 
43%.6 Differences found between both continents could be 
explained by different drug markets, different prescribing 
patterns, and most importantly, by the tool used to measure 
prevalence.7
Several tools have been developed to guide prescrib-
ing, to maximize the efficacy and safety of therapy, and to 
minimize the consequences of using PIMs, including costs, 
hospitalizations, and mortality.8 The Beers criteria (Mark 
Beers, MD) was the first tool, developed in 1991, and last 
updated in 2019 by the American Geriatric Society.9,10 Since 
then, a considerable number of tools have been developed, 
describing not only PIMs, but also drug–drug and drug–
disease interactions.3 Most of these tools are based on explicit 
criteria, ie, are normally more drug- or disease-oriented and 
are developed based on literature review, expert opinions, 
and consensus techniques.3
Cardiovascular diseases ([CVDs] which also include 
cerebrovascular diseases) such as hypertension, coronary 
heart disease, congestive heart failure, stroke, and atrial fibril-
lation are prevalent among the elderly.11 They represent one 
of the leading causes of death worldwide, with 17.7 million 
deaths registered in 2015 (31.0% of all-cause mortality).12,13 
In Europe, 3.9 million people (45.0% of all-cause mortality) 
have died from CVDs in 2016.13
Few studies have identified PIMs in patients with CVD. 
A study conducted in a cardiology service showed that 
20% of hospitalized patients were previously exposed to a 
PIM in the ambulatory setting.14 However, information on 
PIMs associated with risk of cardiovascular adverse events, 
especially with major adverse cardiac and cerebrovascular 
events (MACCE) for elderly is still scarce. Some of these 
medications can increase the risk of cardiovascular events 
or even exacerbate underlying conditions. Our previous 
systematic review showed that there is a restricted number 
of PIMs described addressing their association with the risk 
of cardiovascular adverse events.20 Some pharmacothera-
peutic groups have been established to be associated with 
cardiovascular events such as nonsteroidal anti-inflammatory 
drugs (NSAIDs), antipsychotics, selective calcium chan-
nel blockers, and dopaminergic agents. Unfortunately, the 
prevalence of those PIMs in elderly patients is still unknown.
The primary objective of this study was to assess the 
prevalence of PIMs with risk of MACCE in the elderly. We 
then specifically aimed to study the prevalence of PIMs with 
risk of cardiac and cerebrovascular adverse events (CCVAEs) 
and to study the presence of these PIMs in patients with 
previous history of CVD.
Materials and methods
Study design
A descriptive cross-sectional study was conducted, where a 
convenience sample (based on geographic criteria) of citizens 
living in long-term care facilities (LTCFs) in the region of 
Lisboa e Vale do Tejo and the region of Alentejo and inde-
pendently in their own home (ambulatory) in the region of 
Lisboa e Vale do Tejo, Portugal were invited to participate. 
Citizens’ information (including drug use) was collected 
from two LTCFs in the region of Lisboa e Vale do Tejo and 
two LTCFs in the other region of Alentejo. While, for indi-
viduals who live independently in their own home, citizens’ 
information was collected from their community pharmacy.
Population and sample
The study population (n=904) consisted of 224 residents 
and 680 patients from the community pharmacy and the 
LTCF, respectively. In the LTCF, residents were eligible 
if they were aged 65 or older and living in the facility until 
2017. In the community pharmacy, the study population was 
calculated based on the minimum legal number of inhabit-
ants per pharmacy (3,500 inhabitants) and on the percentage 
of elderly living in the district of Cascais in 2016 (19.6%). 
Moreover, individuals were included if they were aged 65 
or older and had their medication history available in the 
pharmacy database in 2017. We excluded patients if their 
records were out of date, ie, if there were no sales in 2017.
Outcomes’ definition and measurement
Our previous study focused on a systematic review of 
24 PIM-lists, where PIMs associated with CCVAEs and 
MACCE were identified (Table S1 shows the full list of those 
PIMs). As the primary outcome, the presence of PIMs with 
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stroke, transient ischemic attack, myocardial infarction, heart 
failure, and cardiovascular death. A secondary outcome was 
defined as the presence of PIMs with risk of CCVAEs includ-
ing the risk of hypertension, orthostatic or postural hypoten-
sion, bradycardia, QT prolongation, and cardiac arrhythmias.
Data extraction
Data were extracted for sociodemographics (age and 
sex), clinical features (number of comorbidities, previous 
history of CVD, and the presence of dementia), and drug-
related characteristics (number of medications and presence 
of polypharmacy). The previous history of CVD and the 
presence of dementia were defined according to medica-
tion used to treat CVD and dementia, respectively, as a 
proxy. Polypharmacy was defined as taking five or more 
medications.15 Information on comorbidities was validated by 
one member of the research team (JPA) and then confirmed 
by a physician (LHC). For the records with medical diagno-
sis, the validation process was performed by comparing the 
available medical diagnoses with the medication used. When 
information was insufficient to reach a consensus, data were 
considered missing.
Ethics and confidentiality
The use of patients’ medical and pharmacotherapeutic 
records was authorized by the clinical directors of all par-
ticipating institutions. To ensure anonymity, alphanumeric 
codes were used to identify the patients. All research was 
conducted following the principles of the Helsinki Declara-
tion. Ethics approval was obtained from Comissão de Ética 
para a Investigação nas Áreas de Saúde Humana e Bem-Estar 
da Universidade de Évora (document 14017).
Data analysis
The total number of PIMs, total number of patients using 
PIMs, and total number of patients using PIMs with previ-
ous history of CVD were assessed. The most commonly 
described PIMs were analyzed and coded by pharmacothera-
peutic groups, using the WHO ATC classification system.15
Statistical analysis was performed using IBM SPSS 
v.24.0. Descriptive statistics were used, where numerical 
variables were expressed using central tendency and dis-
persion measures (either as mean and SDs, whichever was 
applicable) and categorical variables as absolute and rela-
tive frequencies. Bivariate statistics were used to compare 
both settings regarding differences in sociodemographic, 
clinical, and pharmacotherapeutic features. Chi-squared 
test and Student’s t-test for independent samples were 
used, whichever was applicable considering a 95% CI. For 
numerical variables, normal distribution was also assessed.
The prevalence of PIMs with the risk of CCVAE or 








Total number of older individuals  
Results
Patients’ characteristics
From the initial 904 elderly patients, 63 were excluded from the 
LTCF sample and 161 from the community pharmacy sample 
due to missing data or records which were out of date. The final 
sample consisted of 680 patients, in which most of them were 
female (n=428; 62.9%) with a mean age of 78.4±8.1 years 
(range: 65; 101). Patients had a mean of 3.7±1.8 comorbidi-
ties, approximately 77.0% (n=521) presented with a history 
of CVD, and 10.7% (n=73) also presented with dementia. 
The total number of medications prescribed was 5,112, with 
a mean number of medications taken per patient of 7.5±4.2. 
Table 1 describes the sample’s sociodemographic and clinical 
features and details the differences by settings.
In LTCF, patients were older than in the ambulatory 
setting (85.4±6.5 vs 76.7±7.5; P,0.0001). Patients in 
LTCFs were also more associated with a higher number of 
comorbidities (4.7 vs 3.5 comorbidities/patient; P,0.0001) 
and medications used (10.4 vs 6.8 medications/patient; 
P,0.0001) compared to ambulatory care.
PIMs with risk of CCVAes
After applying the PIM-list specific for CCVAEs, a total 
of 682 PIMs were identified from the overall sample. Most 
of the patients (55.2%) took one PIM with a mean number of 
1.7±1.0 PIMs used per patient. The prevalence of PIMs with 
risk of CCVAEs was 59.4% (n=404) and 47.4% (n=322) of 
patients had a previous history of CVD.
The prevalence of these PIMs among the elderly in 
LTCFs was substantially higher when compared to the 
ambulatory setting (78.1% vs 54.7%; P,0.0001). A similar 
proportion was observed for patients with a previous history 
of CVD (63.5% in LTCFs vs 46.6% in ambulatory setting; 
P,0.0001). These patients were also more prone to using 
two PIMs when compared to patients from ambulatory setting 
(33.6% in LTCFs vs 19.1% in ambulatory setting; P=0.001). 
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In the overall sample, the pharmacotherapeutic groups 
most commonly found associated with cardiovascular risk of 
adverse events were: non-steroidal anti-inflammatory drugs 
([NSAIDs] n=199; 29.7%); antipsychotics (n=118; 17.6%); 
thyroid preparations, ie, levothyroxine (n=70; 10.4%); and anti-
depressants (n=57; 8.5%). Other drug classes were also found 
to a lower extent: peripheral vasodilators, eg, nicergoline and 
pentoxifylline (n=33; 4.9%), natural products, eg, gingko biloba 
(n=25; 3.7%), antiarrhythmics, eg, amiodarone, flecainide, and 
propafenone (n=19; 2.8%); and cardiac glycosides, eg, digoxin 
(n=18; 2.7%). Table 3 describes all the pharmacotherapeutic 
groups with risk of CCVAEs found in the overall sample.
NSAIDs were mostly used by patients recruited from the 
community pharmacy (12.7% in LTCFs vs 36.2% in ambula-
tory setting), as well as thyroid preparations (8.8% in LTCFs 
vs 11.1% in ambulatory setting). Conversely, antipsychotics 
(38.7% vs 9.9% in ambulatory setting), dopaminergic 
agents (3.3% vs 0.6% in ambulatory setting), and cardiac 
glycosides (6.6% vs 1.2% in ambulatory setting) were more 
frequently found in patients from LTCFs.
PIMs with risk of MACCe
From the 682 PIMs identified, more than a half (n=378) were 
associated with risk of MACCE. A mean number of 1.4±0.8 
PIMs were used per patient, with the majority of them using 
between one and two PIMs (92.4%). In the overall sample, 
the prevalence of PIMs with risk of MACCE was 38.8% 
(n=264), and 29.7% (n=202) of patients also had a previous 
history of CVD (Table 2).
The prevalence of these PIMs among the elderly was 
substantially higher in LTCFs compared to the ambulatory 
setting (51.8% vs 35.5%, respectively; P,0.0001). A similar 
proportion was observed for patients with a previous history 
of CVD (40.1% in LTCFs vs 27.1% in ambulatory setting; 
P=0.003).
NSAIDs (n=199; 53.1%) and antipsychotics (n=118; 
31.5%) were the most prevalent drug classes in the overall 
sample. However, antipsychotics were mostly used by 
patients in LTCFs, and NSAIDs by patients from the 
ambulatory setting. To a lower extent, antidepressants (eg, 
venlafaxine), selective calcium channel blockers with 
Table 1 Sociodemographic and clinical features of the Portuguese elderly sample



















Age – mean ± SD, years 78.4±8.1 85.4±6.5 76.7±7.5 ,0.0001a
Male sex – n (%) 252 (37.1) 41 (29.9) 211 (38.9) 0.053
Comorbidities – mean ± sD 3.7±1.8 4.7±2.3 3.5±1.6 ,0.0001a






























Previous history of cardiovascular diseases – n (%) 521 (76.6) 110 (80.3) 411 (75.7) 0.256
Dementia – n (%) 73 (10.7) 25 (18.2) 48 (8.8) 0.001a
Polypharmacy – n (%) 509 (74.9) 135 (98.5) 373 (68.7) ,0.0001a
number of medications – mean ± sD 7.5±4.2 10.4±3.9 6.8±4.0 ,0.0001a
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mainly vascular effects (eg, nifedipine) were also identi-
fied. The individual drugs most commonly found in each 
group were: quetiapine (n=48; 40.7%); ibuprofen (n=46; 
23.1%); diclofenac (n=43; 21.6%); melperone (n=19; 
16.1%); cyamemazine (n=13; 11.0%); etoricoxib (n=20; 
10.0%); and naproxen (n=20; 10.0%). Table 4 summarizes 
all the PIMs with risk of MACCE identified in the overall 
sample and by setting.
No differences were found in the distribution of phar-
macotherapeutic groups. In patients with previous history of 
CVD, 91.7% (LTCFs =22/ambulatory =24) were using nife-
dipine, 81.0% (17/21) venlafaxine, 77.0% (10/13) estrogen, 
76.7% (69/90) antipsychotics, and 76.1% (118/155) NSAIDs.
One of the subpopulations where antipsychotics should 
be avoided is the demented elderly patient. From the 
73 demented patients, more than half (n=39; 53.4%) were 
taking antipsychotics. This value was even higher if we only 
restricted the analysis to LTCFs: 88% (22/25). Conversely, 
a lower proportion of patients in primary care used antipsy-
chotics (n=17; 35.4%). In addition, the type of antipsychot-
ics selected also seemed to be influenced by setting, where 
second-generation antipsychotics were more widely found in 
the ambulatory setting, whilst first-generation antipsychotics 
were most common in LTCFs.
Discussion
This study enabled the possibility of assessing the prevalence 
of PIMs with risk of CCVAEs and MACCE in an elderly 
Portuguese sample and, to the best of our knowledge this is 
the first study focusing on this topic in Europe. Inappropriate 
prescribing is more likely to occur in the elderly, since this 
subpopulation is generally using more medications to treat 
several chronic conditions. In this study, patients presented 
an average of 3.7±1.8 comorbidities and were taking on 
average 7.5±4.2 medications. The majority of these patients 
were taking PIMs with CCVAE risk (59.4%) and almost 
half of them were associated with MACCE risk. It is well-
known that CVDs are frequently found in the elderly and 
are an important cause of morbidity and mortality in these 
patients. Thus, in patients with a previous history of CVD, 
the prevalence of PIM use was also high. A previous study 
focusing on the identification and quantification of PIMs with 
MACCE risk, using tools addressing inappropriate prescrib-
ing, was used to assess the prevalence of these medications 
Table 2 number of patients using PIMs associated with risk of CCVAe or MACCe





PIMs with risk of CCVAe
Total number of PIMs – n (%) 682 (13.3) 185 (12.9) 497 (13.5) –
Mean number of PIMs/patient – mean ± sD 1.7±1.0 1.7±0.9 1.7±1.0 0.409
1 PIM – n (%) 223 (55.2) 54 (50.5) 169 (56.9) 0.409
2 PIMs 113 (28.0) 36 (33.6) 77 (25.9)
3 PIMs 49 (12.1) 12 (11.2) 37 (12.5)
4 PIMs 12 (3.0) 3 (2.8) 9 (3.0)
$5 PIMs 7 (1.7) 2 (1.9) 5 (1.7)
Total number of patients taking PIMs – n (%) 404 (59.4) 107 (78.1) 297 (54.7) ,0.0001a
Total number of patients taking PIMs with previous history of CVD – n (%) 322 (47.4) 87 (63.5) 253 (46.6) ,0.0001a
PIMs with risk of MACCe
Total number of PIMs – n (%) 378 (7.4) 100 (7.0) 278 (7.6) –
Mean number of PIMs – mean ± sD 1.4±0.8 1.4±0.8 1.4±0.8 0.336
1 PIM – n (%) 182 (68.9) 53 (74.6) 129 (66.8) 0.336
2 PIMs 62 (23.5) 11 (15.5) 51 (26.4)
3 PIMs 11 (4.2) 4 (5.6) 7 (3.6)
4 PIMs 6 (2.3) 2 (2.8) 4 (2.1)
$5 PIMs 3 (1.1) 1 (1.4) 2 (1.0)
Total number of patients taking PIMs – n (%) 264 (38.8) 71 (51.8) 193 (35.5) ,0.0001a
Total number of patients taking PIMs with previous history of CVD – n (%) 202 (29.7) 55 (40.1) 147 (27.1) 0.003a
Note: aStatistically significant (P,0.05).
Abbreviations: CCVAe, cardiac and cerebrovascular adverse event; CVD, cardiovascular disease; MACCe, major adverse cardiac and cerebrovascular events; 
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in our sample. This list was driven by a previous systematic 
review that included 24 of the tools currently available (eg, 
Beers criteria, START/STOPP criteria, and Zhan criteria). 
Different studies, in different health care settings, have also 
investigated the prevalence of PIMs, but did not focus on a 
specific negative outcome. In Portugal, da Costa et al (2016) 
used different criteria to assess the prevalence of PIMs in 
elderly residents in nursing homes. They found that using 
Beers criteria, Beers criteria adapted to Portugal and START/
STOPP criteria, the prevalence of PIMs was 85.1%, 60.3%, 
and 75.4%, respectively. These patients had an average age 
of 84.7±6.35 years and a mean of 4.1±2.14 comorbidities.16 
Another study, conducted by Nyborg et al (2017), showed 
that the prevalence of PIMs in Norwegian elderly was 
43.8%, using the Norwegian General Practice Nursing Home 
(NORGEP-HN) criteria.17 In the outpatient setting, in the 
USA, the prevalence of PIMs was 23.3% and 16.2% using 
the Beers criteria and Zhan criteria, respectively.18
The elderly tend to present with multiple chronic condi-
tions, which increases the odds of using multiple medications. 
Many patients in this study had a previous history of CVDs 
and 10% also presented with dementia. The most commonly 
prescribed pharmacotherapeutic groups were NSAIDs and 
antipsychotics. NSAIDs are known to be associated with 
exacerbation of heart failure and to cause major cardiac events 
like stroke and myocardial infarction. Among NSAIDs, selec-
tive cyclooxygenase-2 (COX-II) inhibitors (eg, etoricoxib and 
celecoxib) are associated with an increased risk of myocardial 
infarction.19 In this study, 15.5% of patients took selective 
COX-II inhibitors. The 2015 Beers criteria alert for the poten-
tially inappropriate prescribing of antipsychotics in patients 
with dementia. This pharmacotherapeutic group is known to 
be associated with an increased risk of stroke.10 Even though 
not many demented patients were found in our sample, almost 
77.0% of them were taking antipsychotics. These medica-
tions were commonly used in patients in LTCFs, where more 
frail elderly patients can be found, and are normally used in 
combination with other high-risk medications for cardiovas-
cular events, such as dopaminergic agents or antidepressants.
We assume patients in LTCFs seem to have a higher risk 
of MACCE occurrence because of a higher prevalence of 
PIMs’ use, in addition, a higher prevalence of medications 
Table 3 Most commonly prescribed pharmacotherapeutic groups associated with risk of CCVAEs in both settings




Antiadrenergic agents (centrally acting) C02A 12 (1.8) 0 (0.0) 12 (2.5)
Antiarrhythmics (Class I and III) C01B 19 (2.8) 5 (2.8) 14 (2.9)
Antidepressants n06A 57 (8.5) 19 (10.5) 38 (7.8)
Antipsychotics n05A 118 (17.6) 70 (38.7) 48 (9.9)
Anxiolytics n05B 13 (1.9) 5 (2.8) 8 (1.6)
Beta blocking agents C07A 5 (0.7) 0 (0.0) 5 (1.0)
Capillary stabilizing agents C05C 8 (1.2) 2 (1.1) 6 (1.2)
Cardiac glycosides C01A 18 (2.7) 12 (6.6) 6 (1.2)
Dopaminergic agents n04B 9 (1.3) 6 (3.3) 3 (0.6)
Drugs affecting bone structure and mineralization M05B 4 (0.6) 1 (0.6) 3 (0.6)
hormones and related agents l02A 13 (1.9) 0 (0.0) 13 (2.7)
Muscle relaxants (centrally acting) M03B 13 (1.9) 3 (1.7) 10 (2.1)
natural products – 25 (3.7) 6 (3.3) 19 (3.9)
Nonsteroidal anti-inflammatory drugs M01A 199 (29.7) 23 (12.7) 176 (36.2)
Other cardiac preparations C01e 4 (0.6) 1 (0.6) 3 (0.6)
Other systemic drugs for obstructive airway diseases r03D 7 (1.0) 0 (0.0) 7 (1.4)
Peripheral vasodilators C04A 33 (4.9) 8 (4.4) 25 (5.1)
Psychostimulants n06B 6 (0.9) 1 (0.6) 5 (1.0)
selective calcium channel blockers with direct cardiac effects C08D 9 (1.3) 0 (0.0) 9 (1.9)
Selective calcium channel blockers with mainly vascular effects C08C 24 (3.6) 3 (1.7) 21 (4.3)
Thyroid preparations h03A 70 (10.4) 16 (8.8) 54 (11.1)
Urologicals g04B 4 (0.6) 0 (0.0) 4 (0.8)
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with higher odds of drug–drug and drug–disease interactions 
was found. Additionally, these elderly patients have more 
comorbidities and use more medications increasing the car-
diovascular risk for future events. These findings suggest 
that more attention should be paid to tertiary care to optimize 
medication, by reducing the use of these drugs.
The high prevalence of PIMs with the risk of CCVAEs 
and MACCE may suggest that interventions targeted at 
medication misuse need to be further developed and imple-
mented into practice. However, we should keep in mind 
that the existing criteria, in most cases, do not explicitly 
assess patient-related indicators (eg, weight, cardiac distur-
bances, and patients with high cardiovascular risk score) or 
drug-related indicators (eg, route of administration, dosage, 
and frequency of exposure). A good example is levothyrox-
ine. This drug does not have an alternative suggested in the 
lists and sometimes is considered as potentially inappropriate, 
given the risk for cardiac arrhythmias. This is surely a draw-
back in practice if we consider the likelihood of a clinician 
basing his decisions on such lists. Perhaps more complex 
and tailored indicators should be developed to target high-
risk patients where the PIMs identified are indeed poten-
tially inappropriate for that specific individual. A possible 
example of an intervention could be the familiarization or 
even the inclusion of these last indicators in an information 
and technology strategy to foster de-prescribing during the 
Table 4 Most commonly prescribed PIMs associated with risk of MACCE in both settings
PIMs associated with risk 
of MACCE – n (%)
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medication review process, where full clinical and laboratory 
details would be embedded in the software.
Limitations
This study has some limitations. First, to assess drug use in 
the ambulatory setting, we reported community pharmacy 
data which limited our ability to extract accurate information 
on patients’ comorbidities, and consequently the capacity 
to judge drug–disease interactions. Second, the number 
of comorbidities, the previous history of CVD, and the 
presence of dementia were based on the analysis of the 
pharmacotherapeutic regimen of each patient available in 
the community pharmacy and LTCF. We therefore believe 
that comorbidities are more likely to be underreported and 
some misclassification bias could also be present. However, 
to minimize this bias, we have assessed comorbidities as 
a group (history of CVD or dementia), instead of using 
individual diagnoses from both settings. Third, we had 
incomplete information on all drug-related variables in 
both settings, which did not allow for the extraction of the 
frequency of exposure. Finally, although we had a good 
sample size, the results should only be generalized to elderly 
patients included in those regions (restricted to both settings) 
and not nationwide.
Conclusion
More than half of the elderly included in our sample were 
using PIMs with risk of CCVAEs, and approximately 40% 
of those were associated with risk of MACCE. About half of 
patients with a previous history of CVD took PIMs. The most 
commonly used PIMs with risk of MACCE were NSAIDs 
and antipsychotics, which accounted for almost half of the 
total drugs assessed in this sample. Future interventions and 
more tailored tools for the management of drug therapy in 
elderly patients with CVD are of major importance.
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Table S1 Potentially inappropriate medications with risk of cardiovascular adverse events in the elderly
Adverse drug reactions Potentially inappropriate medications (medication classes or individual drugs)





Hormones and related agents [L02A]
Estrogens [L02AA]






Myocardial infarction NSAIDs [M01A]
COX-II Inhibitors [M01AH]
Amphetamines




sudden cardiac death Propulsives [A03F]
Domperidone (.30 mg/d) [A03FA03]
heart failure NSAIDs [M01A]
COX-II Inhibitors [M01AH]
Naproxen (long-term use) [M01AE02]
Piroxicam (long-term use) [M01AC01]




Antiarrhythmics (Class I and III) [C01B]
Disopyramide [C01BA03]
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Adverse drug reactions Potentially inappropriate medications (medication classes or individual drugs)
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Agents acting on arteriolar smooth muscle [C02D]
Hydralazine [C02DB02]










Drugs used in benign prostatic hypertrophy [G04C]
Terazosin [G04CA03]
Hypnotics and sedatives [N05C]
Clomethiazole [N05CM02]
Propiomazine [N05CM06]
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Adverse drug reactions Potentially inappropriate medications (medication classes or individual drugs)


















Beta blocking agents [C07A]
Sotalol [C07AA07]
Other cardiac preparations [C01E]
Ivabradine [C01EB17]
















Selective calcium channel blockers with direct cardiac effects [C08D]
Diltiazem [C08DB01]
Verapamil [C08DA01]
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Note: *no ATC code available.
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